Search

everythinglearnresearchcommunity

for

Search:↓

The user is experiencing hair thinning and is considering using minoxidil. They are concerned about the progression of hair loss and whether it will lead to complete baldness.

An 18-year-old has been using topical finasteride and minoxidil for hair loss without noticeable improvement and is considering oral finasteride. Some users suggest starting oral finasteride at 18 is fine, especially if puberty is complete, while others recommend caution and consulting a specialist.

The conversation discusses the effectiveness of minoxidil for hair loss after one month of use, with a user questioning if complete hair regrowth is possible and another suggesting the perceived improvement may be due to lighting differences rather than actual hair growth.

The conclusion of this conversation is that after 90 days of using 5% topical minoxidil, dermarolling once a week, and taking 1mg of oral finasteride daily, the user "M3ga_Shniz" has experienced a complete stop in hair loss thanks to finasteride. They are hopeful that their temples will continue to grow more as they continue with the treatment.

A user shared their experience with Finasteride for hair loss, noting a significant reduction in DHT levels and a complete loss of libido without other side effects. Another user agreed, discussing the negative impact on sexual drive and criticizing the community's attitude towards discussing side effects.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The conversation is about a product called FLEAVA, found in a Facebook ad, and whether it is effective or just another scam. One user believes it is likely a scam and mentions that such products usually don't compete with Minoxidil.

Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

The user shared their 3-month progress using Minoxidil, Finasteride, rosemary oil, and dermarolling, reporting no side effects and healthier, thicker hair. They recommend these treatments and plan to complete their hairline in 6-9 months.

A user shared their 11-year journey with alopecia, using finasteride, dutasteride, and a hair transplant. They encouraged others not to panic, noting that hair miniaturization can take over 15 years to complete.

The user "BigBashMan" shared their progress pictures of hair regrowth after using a regimen of finasteride, minoxidil, microneedling, and Nizoral shampoo for about a year. They are happy with the results and attribute the microneedling as a potential factor for regrowth. Another user commented that they may see complete scalp coverage in another year.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The user is exploring KX-826 as a potential hair loss treatment due to intolerance to FDA-approved drugs like Minoxidil and finasteride. They seek fundamental help and information about KX-826.

A 19-year-old male experienced hair shedding after one year on dutasteride and is considering adding topical minoxidil despite scalp itching. Users suggest continuing dutasteride, maintaining a consistent hair routine, and possibly increasing minoxidil dosage.

The user reports that after 4 months of microneedling, 10 months of Minoxidil, 2 years of finasteride, and using ketoconazole 3 times a week, their hair has become less dense in the treated areas. Despite initial shedding and continued treatment, they have not seen improvement and feel their body is resistant to the medications.

A 22-year-old male has been experiencing hair thinning since 18 and was prescribed 50mg oral spironolactone for hair loss and high blood pressure, despite inquiring about finasteride. A reply suggests that spironolactone is less effective than finasteride and minoxidil for hair loss and recommends seeking a second medical opinion.

The conversation discusses hair loss treatments, specifically using finasteride, minoxidil, and microneedling. Recommendations for durable microneedling tools include the Derminator 2 and Dr. Pen.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

Dutasteride improved hair density and thickness in men who didn't respond to finasteride, with some experiencing transient sexual dysfunction. Users discussed switching from finasteride to dutasteride, noting initial shedding but eventual hair improvement.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

The user saw no significant changes in hair loss after three months on 3mg Dutasteride, having previously used Finasteride and 0.5mg Dutasteride. They plan to continue the high dose for a year despite concerns about side effects and diminishing returns.

Caffeine shampoos show comparable results to Minoxidil and may enhance its effects when used together. Caffeine can be detected in the scalp up to 24 hours after a 2-minute application, making it an affordable treatment option.

Minoxidil and caffeine may interact, affecting hair growth results. Users shared mixed experiences, with some noticing improvements without caffeine and others still seeing results despite coffee consumption.

The post discusses an individual's 11-month hair restoration journey using oral finasteride, topical minoxidil and finasteride, micro-needling, biotin tablets, and ketoconazole shampoo. Despite mixed reactions and skepticism from others, the individual expresses gratitude for support and claims progress in hair growth.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The user has been using finasteride for a year but is experiencing thinning in some areas and is unsure how to proceed. Suggestions include trying minoxidil for regrowth or consulting a dermatologist about adjusting the finasteride dosage.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.